Market News & Trends
Cardiovascular Disease - Innovation Within Dyslipidemia, Heart Failure & Thrombosis Set to Reduce High CVD Mortality Rate
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension,…
Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study
Mateon Therapeutics, Inc. recently announced results from its second scheduled interim analysis of the ongoing Phase 2/3 FOCUS study evaluating CA4P in combination with bevacizumab…
Fate Therapeutics Announces Issuance of Patent Covering Use of Viral Transduction Enhancers
Fate Therapeutics, Inc. recently announced the US Patent and Trademark Office has issued US Patent No. 9,675,641 covering the use of prostaglandins as viral transduction…
Monsanto & ToolGen Announce Global Licensing Agreement
Monsanto Company and ToolGen, Inc. recently announced the companies have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop…
Portola Pharmaceuticals Announces BLA Resubmission Accepted for Review
Portola Pharmaceuticals Inc. recently announced the US FDA has found its resubmitted Biologics License Application (BLA) for AndexXa (andexanet alfa) to be acceptable for review,…
Fortress Biotech Forms New Subsidiary to Develop Novel AAV Gene Therapy Treatments
Fortress Biotech, Inc. recently announced the formation of a new subsidiary company, Aevitas Therapeutics, Inc., to develop novel gene therapy approaches for complement-mediated diseases. The…
PolyPid Completes Enrollment in Phase Ib/II Study of D-PLEX
PolyPid Ltd. recently announced the completion of enrollment in its Phase Ib/II study of D-PLEX (Doxycycline/Polymer-Lipid Encapsulation Matrix), the company’s lead product candidate, for the…
Manufacturing Process Scale-Up for Phase III: Clear Sailing or Storms Ahead?
Some drug developers diligently design scalability into their formulations from day one and are fully prepared for larger-scale production during Phase III. Essentially, their only…
Galena Biopharma Enters Merger Agreement With SELLAS Life Sciences
Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd recently announced they have entered into an all stock definitive merger agreement under which SELLAS will…
Humanigen Announces Completion of Bioavailability Study
Humanigen, Inc. recently announced it has completed enrollment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is a key…
SGS Expands & Increases Capacity 50%
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, is expanding its facility in Lincolnshire, in the northern suburbs of Chicago, IL. The expansion…
Avista Pharma Solutions Completes Expansion of Analytical Laboratories
Avista Pharma Solutions, Inc. recently announced that the expansion and upgrades to the Analytical Laboratories at its Durham, NC, facility are now complete. These enhancements…
Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity
Cambrex Corporation recently announced it is to invest $24 million in a new facility to manufacture highly potent APIs (HPAPIs) at its Charles City, IA,…
Aclaris Therapeutics Acquires Confluence Life Sciences
Aclaris Therapeutics Acquires Confluence Life Sciences Aclaris Therapeutics, Inc. recently announced it has acquired Confluence Life Sciences, Inc., a privately held biotechnology company focused on…
WuXi AppTec Immunotherapy Report: Biotech Sector Will Drive Biggest Advancements in Decades on Cancer Treatments
Small nimble biotechs to introduce a “golden age” of next-generation therapies like CAR-T, combination therapies, innate immune system approaches, and newer check-point inhibitors …
Biological Bypass Shows Promise in Coronary Artery Disease
A new gene therapy that targets the heart and requires only one treatment session has been found safe for patients with coronary artery disease, according…
DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients
DBV Technologies recently announced that the first patient has been enrolled in EPITOPE (EPIT in TOddlers with PEanut Allergy), a global, Phase III clinical trial…
WuXi’s Pharmaceutical Development Services Division Merges With STA
STA Pharmaceutical Co., Ltd. – a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing…
US Oncology Research & Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
Epizyme, Inc. and US Oncology Research recently announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma…
CrownBio Launches Innovative Inflammatory Disease Models to Advance Preclinical Research
Crown Bioscience recently announced the launch of preclinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) to help inform decision-making in preclinical drug…
